Berlin-based Amboss, the resource for medical education and clinical decision-making in Germany and the US, has closed a €240 million financing round with new long-term investors.
Amboss said the investment will support “the exploration of additional international markets and the expansion of its offering to nurses and other health care professionals.”
Amboss recently converted to a European stock corporation (SE) and completed a financing round with new primary investors Kirkbi, M&G Investments and Lightrock with participation from existing shareholders.
Benedikt Hochkirchen, co-founder and co-CEO of Amboss said: “We choose investors who are committed to our long-term vision and very flexible in the investment duration.
“Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond.
“Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy.”
In 2024, Amboss acquired Novaheal, a start-up in the nursing field, and NEJM Knowledge+, a board exam prep product for residents in the US.
“Over 1 million users in more than 180 countries trust Amboss for clinical decision-making and medical education.,” said Amboss.
“Every second inpatient treatment in Germany is carried out by a physician supported by Amboss. In the US, the majority of medical students use Amboss to successfully prepare for exams, and score higher than with other question banks. 25% of first-year US residents depend on Amboss to help them provide excellent patient care.
“The concept is as simple as it is successful: Medical experts distill relevant medical knowledge, and AI-supported technology places it directly at users’ fingertips.”
Peter Bason, Head of Private Capital at Kirkbi, said: “We have followed Amboss’ impressive growth journey, from its successful US expansion to its strong focus on innovation.
“Its unique platform is becoming a vital tool for both medical students and health care professionals, supporting learning and decision-making at every stage. We are excited to partner with other experienced technology and growth investors to back Amboss’ visionary leadership team in their mission of empowering the next generation of health care professionals worldwide.”